Perceptive Advisors’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$39.7M Sell
1,597,383
-397,507
-20% -$10.3M 0.78% 30
2025
Q4
$50.7M Buy
1,994,890
+407,000
+26% +$9.08M 0.9% 34
2025
Q3
$25.6M Sell
1,587,890
-550,000
-26% -$8.9M 0.74% 38
2025
Q2
$34.2M Sell
2,137,890
-706,182
-25% -$10.7M 1.27% 22
2025
Q1
$48.6M Buy
2,844,072
+704,873
+33% +$14.7M 1.72% 14
2024
Q4
$53M Sell
2,139,199
-239,563
-10% -$6.8M 1.46% 22
2024
Q3
$67.8M Buy
2,378,762
+454,976
+24% +$13.4M 1.43% 22
2024
Q2
$50.8M Sell
1,923,786
-1,039,426
-35% -$29.6M 1.22% 24
2024
Q1
$95.7M Buy
2,963,212
+635,130
+27% +$23.2M 1.68% 17
2023
Q4
$98.1M Sell
2,328,082
-1,486,609
-39% -$54.7M 2.19% 9
2023
Q3
$146M Buy
3,814,691
+1,290,908
+51% +$29.2M 4.88% 3
2023
Q2
$47.9M Buy
2,523,783
+1,231,925
+95% +$23M 1.39% 20
2023
Q1
$20M Buy
1,291,858
+1,141,858
+761% +$19.8M 0.59% 44
2022
Q4
$2.66M Buy
+150,000
New +$1.89M 0.07% 83
2021
Q1
Sell
-1,400,000
Closed -$64.7M 149
2020
Q4
$64.7M Hold
1,400,000
0.69% 38
2020
Q3
$49.3M Buy
1,400,000
+300,000
+27% +$9.02M 0.72% 37
2020
Q2
$26.8M Buy
+1,100,000
New +$23.6M 0.43% 53

Other funds holding IMVT

Perceptive Advisors's IMVT Position: Q1 2026 in Review

Perceptive Advisors reduced its Immunovant (IMVT) stake by 20% in Q1 2026, selling an estimated $10.3M and leaving 1,597,383 shares worth $39.7M. The position accounts for 0.78% of the portfolio, ranked #30.

Perceptive Advisors first reported a position in IMVT in Q2 2020 and has held it in 17 quarters since. The position peaked at $146M in Q3 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Perceptive Advisors held 1,597,383 shares of Immunovant worth $39.7M as of Q1 2026.
  • Perceptive Advisors sold 397,507 Immunovant shares in Q1 2026, an estimated $10.3M.
  • Immunovant made up 0.78% of Perceptive Advisors's portfolio in Q1 2026, its #30 holding.
  • Perceptive Advisors first reported a position in Immunovant in Q2 2020 and has held it in 17 quarters since.
  • Perceptive Advisors's Immunovant position peaked at $146M in Q3 2023.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.